We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces cell arrest. To further explore the latter function, we studied whether MMP-9 influences the gene-expression profile in CLL. Microarray analyses rendered 131 differentially expressed genes in MEC-1 cells stably transfected with MMP-9 (MMP-9-cells) versus cells transfected with empty vector (Mock-cells). Ten out of twelve selected genes were also differentially expressed in MEC-1 cells expressing the catalytically inactive MMP-9MutE mutant (MMP-9MutE-cells). Incubation of primary CLL cells with MMP-9 or MMP-9MutE also regulated gene and protein expression, including CD99, CD226, CD52, and CD274. Because CD99 is involved in leukocyte transendothelial migration, we selected CD99 for functional and mechanistic studies. The link between MMP-9 and CD99 was reinforced with MMP-9 gene silencing studies, which resulted in CD99 upregulation. CD99 gene silencing significantly reduced CLL cell adhesion, chemotaxis and transendothelial migration, while CD99 overexpression increased cell migration. Mechanistic analyses indicated that MMP-9 downregulated CD99 via binding to α4β1 integrin and subsequent inactivation of the Sp1 transcription factor. This MMP-9-induced mechanism is active in CLL lymphoid tissues, since CD99 expression and Sp1 phosphorylation was lower in bone marrow-derived CLL cells than in their peripheral blood counterparts. Our study establishes a new gene regulatory function for MMP-9 in CLL. It also identifies CD99 as an MMP-9 target and a novel contributor to CLL cell adhesion, migration and arrest. CD99 thus constitutes a new therapeutic target in CLL, complementary to MMP-9.
Introduction
Progression of chronic lymphocytic leukemia (CLL) is determined by infiltration of malignant cells into lymphoid organs [1, 2] . Interaction with the microenvironment in these organs is beneficial for CLL cells, since they receive proliferative signals and acquire resistance to chemotherapy.
Several molecules regulate the migration and organ localization of these cells, including integrins, chemokines, and matrix metalloproteinase-9 (MMP-9) [3] . CLL cells synthesize the proform and the activated form of MMP-9 (hereafter MMP-9 for either form) [4] [5] [6] . Although mostly secreted into the medium, MMP-9 is also present at the CLL cell surface, where it binds to a α4β1 integrin (CD49d/ CD29)/CD44 V complex [4] [5] [6] [7] . We previously showed that MMP-9-α4β1 integrin interaction contributes to CLL pathology, as it induces cell survival (by a noncatalytic mechanism) and regulates cell migration [7] [8] [9] [10] . While constitutive MMP-9 is necessary for CLL cell migration, elevated levels of MMP-9 inhibit in vitro and in vivo migration, favoring cell arrest [7, 10] . This was demonstrated with primary CLL cells incubated with MMP-9 and with MEC-1 cells stably transfected with empty vector (Mock-cells) or with MMP-9 (MMP-9-cells) [10] . The mechanism accounting for the migration inhibitory effect of MMP-9 is not known, but it includes modulation of several molecules (RhoAGTPase, Akt, ERK, FAK, and PTEN) [10] . CLL cell-bound MMP-9 levels increase in lymphoid organs, likely because cells in the microenvironment produce MMP-9 and several factors in these locations upregulate MMP-9 synthesis [6, 11, 12] .
We have also reported that incubation of CLL cells with a catalytically dead MMP-9 mutant (MMP-9MutE) [13] or transfection of MEC-1 cells with this mutant (MMP9MutE-cells) partially affected signaling pathways and cell homing [10, 14] . These previous results suggested that additional noncatalytic MMP-9 activities and local high-MMP-9 expression contribute to CLL cell retention in lymphoid organs and disease progression. Nonproteolytic functions have also been reported for other MMPs, including MMP-1, MMP-2, MMP-3, MMP-12, and MMP-14 [15] [16] [17] [18] . These evidences prompted us to explore new functions of MMP-9 in CLL, particularly those that may contribute to malignant cell arrest in lymphoid niches.
In this report we performed gene expression analyses using MEC-1 cell transfectants and primary CLL cells. We show that MMP-9 regulates genes and proteins by means of catalytic and noncatalytic activities and we have focused on genes possibly involved in cell migration. We have identified CD99 as a new MMP-9 target and have determined the mechanism involved in its regulation by MMP-9. We further show that this mechanism is active in lymphoid tissues. Moreover, functional analyses revealed that CD99 is a novel molecule involved in CLL cell adhesion and migration, thus contributing to disease progression.
Results

MMP-9 regulates gene and protein expression in MEC-1 cells via catalytic and noncatalytic activities
To address the possibility that MMP-9 influences gene expression in CLL cells, we performed gene microarray analyses using total RNA from MEC-1 Mock-cells and MMP-9-cells. Initial analyses with normalized, unfiltered, values rendered 383 differentially expressed genes (172 upregulated, 211 downregulated) in MMP-9-cells, compared to Mock-cells (GSE78174). From these, we selected those genes whose expression change was ≥2-fold, resulting in 131 genes (35 upregulated and 96 downregulated) (Fig.  1a and Supplementary Table S1 ). MMP-9 was the most upregulated gene (73-fold change), confirming the validity of the analysis. Functional allocation of these 131 genes was achieved using the DAVID database and the biological process (BP_FAT) category of Gene Ontology. Upon discarding nonsignificantly enriched processes, these analyses indicated that genes regulated by MMP-9 were mainly involved in intracellular signaling and immune response (16 genes each), cell adhesion (13 genes), cell motion (8 genes), and chemotaxis (5 genes), all potentially related to CLL pathology (Fig. 1b) . The specific genes allocated to each of these categories and their respective fold-change expression are listed in Supplementary Table S2 .
To validate the microarray results, we randomly selected several genes among the most upregulated or downregulated (Supplementary Table S1 ) for quantitative polymerase chain reaction (qPCR) analyses. We also validated genes with known or potential functions in CLL, as well as genes involved in cell migration. These included CD226, with a role in natural killer cell function in CLL [19] ; CD274, involved in CLL immune synapse [20] ; IL-10, with immunoregulatory function and associated to CLL patient survival [21] ; CD52, considered a CLL therapeutic target [22] ; CXCR3, involved in CLL cell chemotaxis and with possible prognostic value [23] ; and CD99, with a known role in leukocyte diapedesis but with no described function in CLL [24] [25] [26] . qPCR analyses confirmed the significant upregulation of DDAH1, LPP, and LRRC16A and the significant downregulation of CD99, CD226, STAP1, ADAM23, CD274, IL10, CD52, CCR8, and CXCR3 in MMP-9-cells, compared to Mock-cells (Fig. 1c) . To determine whether the MMP-9 enzymatic activity was required for the gene regulatory property we analyzed the expression of these genes in MMP-9MutE-cells, which carry the catalytically dead mutant MMP-9MutE [13] . Figure 1c shows that, with the exception of CD52, all other genes were significantly up or downregulated as in MMP-9-cells, albeit the extent of the effect was more limited in MMP-9MutE cells. Since MMP-9 and MMP-9MutE are expressed at similar levels in the transfectants [14] , the contribution of the catalytic domain may amplify the gene regulatory effect.
We then studied whether MMP-9 and MMP-9MutE also regulated protein expression. CD99, CD226, CD274, CD52, and CXCR3 were chosen for these studies, based on their mentioned possible relevance in CLL pathology. Because these proteins mainly function at the cell surface we first determined their expression by flow cytometry. Membrane expression of CD274 was very low in MEC-1 cells and no significant changes could be properly detected. Cell surface expression of CD99, CD226, and CXCR3 was significantly reduced in MMP-9-cells and, to a lesser extent, in MMP-9MutE-cells, compared to Mock-cells (Fig. 1d) . Surface expression of CD52 was only significantly reduced in MMP-9-cells (Fig. 1d ), in agreement with the qPCR results. Analysis of the total cellular levels of some of these proteins by Western blotting showed the significant reduction of CD99 and CD274 expression in MMP-9-cells and MMP-9 and MMP-9MutE regulate gene and protein expression in primary CLL cells
We next studied whether MMP-9 and MMP-9MutE regulated gene expression in primary CLL cells. CLL cells were incubated with these recombinant proteins for 24 h and gene expression was analyzed by qPCR. As observed for MEC-1 cells, MMP-9 upregulated LPP and LRRC16A and downregulated CD99, CD226, ADAM23, CD274, and CD52, while DDHA1, STAP1, IL10, CCR8, and CXCR3 were not differentially modulated (Fig. 2a) . MMP-9MutE also significantly downregulated CD99 and CD274 but not the other genes, compared to control cells (Fig. 2a) . Analyses by flow cytometry indicated that incubation of CLL cells with MMP-9 for 24 or 48 h significantly reduced the cell surface expression of the selected proteins CD99, CD226, CD274, and CD52, compared to control cells (Fig.  2b) . Incubation with MMP-9MutE diminished the surface expression of CD99, CD274, and CD52 (Fig. 2b) . Both MMP-9 and MMP-9MutE significantly reduced the total cellular content of CD99, CD226, and CD274, determined by Western blotting (Fig. 2c) . Collectively, these results established that MMP-9 regulated gene and protein expression in MEC-1 cell transfectants and primary CLL cells, by means of catalytic and/or noncatalytic activities.
Further analyses on the regulation of the MMP-9 target gene CD99
The GO analyses shown in Fig. 1b indicated that many genes regulated by MMP-9 were related to cell adhesion and migration. Because we previously showed that elevated levels of MMP-9 impair CLL cell migration [7, 10, 14] , we studied whether this impairment involved some of the newly identified MMP-9 target genes. Among these, CD99 is important for leukocyte extravasation [24] [25] [26] , but its role in CLL is unknown. We thus selected CD99 for further functional and mechanistic studies.
To first confirm the interconnection between MMP-9 and CD99, we transfected MMP-9-cells with control or two MMP-9-specific siRNAs and measured the resulting levels of CD99. qPCR analyses confirmed that both siRNAs significantly reduced MMP-9 mRNA expression after 24 h, with values progressively recovering after 48 and 72 h (Fig.  3a) . Since MMP-9 1 siRNA was more efficient it was chosen for subsequent experiments. Gelatin zymography analyses indicated that MMP-9 levels were also reduced after 24 and 48 h (34% and 33%, respectively), compared to control cells (Fig. 3b) . In correlation with MMP-9 reduction, CD99 expression significantly increased after 48 h of MMP9 silencing, both at the total cellular level (36%) (Fig. 3b ) and at the cell surface (18%) (Fig. 3c) . Importantly, transfection of primary CLL cells (3 patients) with MMP-9 1 siRNA significantly decreased (33%) MMP-9 mRNA after 24 h, with the concomitant increase (20%) of CD99 mRNA after 48 h (Fig. 3d) . At this time, the levels of MMP-9 protein were also significantly reduced (65%) in the siRNAtransfected cells, with a parallel increase on the expression of total (25%) (Fig. 3e) and surface (14%) (Fig. 3f ) CD99 protein.
CD99-I is the major isoform expressed in MEC-1 cells and is involved in transendothelial migration
We next studied the possible involvement of CD99 in cell migration. Because the reported CD99-I (32 kDa) and CD99-II (28 kDa) isoforms may play distinct migratory roles in other cell systems [26, 27] , we first examined the expression of these isoforms in MEC-1 cells. qPCR analyses showed the expression of CD99-I in Mock-cells and, at lower levels (0.2-fold less) in MMP-9-cells (Fig. 4a ). In both cell types, CD99-II was hardly detected, while it was present in monocytes, used as control for oligonucleotide validation (Fig. 4a ). In agreement with the results shown in Figs. 1e and 3b with the DN16 antibody, additional analyses using the anti-CD99 antibody 12E7 confirmed the presence of a single 32 kDa CD99 band in MEC-1-cells, while 12E7 recognized both CD99 isoforms in monocyte and Jurkat lysates (Fig. 4b) . Therefore, subsequent studies were focused on CD99-I, hereafter called CD99.
For functional studies, we transfected Mock-cells with two different siRNAs for CD99. qPCR analyses indicated that both siRNAs reduced CD99 expression (87.4% and 57.4%, respectively) compared to control siRNA values normalized to 1 (Fig. 4c ). CD99 protein was also reduced, Ctrol control, MFI mean fluorescence intensity; *P < 0.05; **P < 0.01; ***P < 0.001 both at the total cellular level ( Fig. 4d ) and at the cell surface (Fig. 4e) . CD99 downregulation diminished Mock-cell transendothelial migration in response to CCL21 to 11.8% (siRNA 1 ) and 15.2% (siRNA 2 ), compared to the migration of Mock-cells transfected with control siRNA (18.3%) (Fig.  4f ). To confirm these results, we overexpressed CD99 in MMP-9-cells, since they have low-CD99 expression and impaired migration [10, 14] . Transfection of MMP-9-cells with a lentivirus containing CD99 cDNA increased CD99 surface expression by 40%, compared to cells transfected with empty lentivirus (Fig. 4g ). CD99 overexpression significantly increased (36%) the transendothelial migration of MMP-9-cells, compared to control cells (Fig. 4h) . Fig. 5a) , confirming the results shown in Fig. 2c . CLL cells were transfected with control siRNA or two CD99 siRNAs and analyzed by Western blotting and flow cytometry. These analyses confirmed the significant reduction of CD99 at the total cellular level (33.5% and 24.9%, respectively, for CD99 1 and CD99 2 ) (Fig. 5b ) and at the cell surface (35.6% and 21%, respectively) (Fig. 5c ). Both CD99 siRNAs reduced CLL transendothelial migration, compared to cells transfected with control siRNA (35% and 27.4% reduction for CD99 1 and CD99 2 , respectively) (Fig. 5d) . The role of CD99 in CLL cell migration was further confirmed by performing chemotaxis assays, which showed that both CD99 siRNAs diminished (52% and 42%, respectively) CLL cell chemotaxis in response to CCL21 (Fig. 5e) .
In other cell systems, CD99 was shown to modulate integrin-mediated cell adhesion [27, 28] . To determine if CD99 performed this function in CLL, we first analyzed the adhesion of Mock-cells and MMP-9-cells to VCAM-1 and FN-89, two α4β1 integrin ligands [6] . Figure 5f shows that MMP-9-cells (low-CD99 expression) displayed significantly lower adhesion to these substrates than Mockcells. In agreement with this, silencing CD99 in primary CLL cells significantly reduced cell adhesion to VCAM-1 and FN-H89, compared to cells transfected with control siRNA (Fig. 5g) . Collectively, the gene silencing and overexpression experiments clearly demonstrated the novel role of CD99 in CLL cell migration and adhesion. 
CD99 downregulation requires binding of MMP-9 to α4β1 integrin
We next studied the mechanism involved in the regulation of CD99 by MMP-9. Because binding of MMP-9 (or MMP9MutE) to α4β1 integrin induces survival signaling in CLL cells [8] , we determined whether regulation of gene expression by MMP-9 also involved α4β1. CLL cells (6 patients, >30% α4 integrin expression) were treated or not with MMP-9 and CD99 expression (mRNA and protein) upon incubation with MMP-9 was normalized to 1. Blocking the binding of MMP-9 to α4β1 integrin with the HP2/1 mAb prevented the downregulation of CD99 mRNA (Fig. 6a ) and CD99 surface expression (Fig. 6b) , observed in the absence of HP2/1. In both cases, the Ig isotype control had no effect.
To confirm these results, we transfected CLL cells with two α4 integrin-specific siRNAs. Both siRNAs significantly reduced α4 expression (average 37% and 34% reduction, 6 MMP-9-cells were infected with lentiviral particles (LV) alone (Ctrol) or containing CD99-I/CD99-II cDNA, and CD99 expression analyzed after 72 h by flow cytometry. h The transendothelial migration of LV-infected MMP-9-cells, in response to CCL21, was determined by flow cytometry. Ctrol control, MFI mean fluorescence intensity. *P < 0.05; **P < 0.01; ***P < 0.001 compared to cells transfected with control siRNA (Fig. 6c) . Surface expression of α4 integrin at this time was also significantly decreased by both siRNAs (Fig. 6d) . The expression of cell-bound MMP-9 on cells transfected with α4 or control siRNAs was also analyzed without (endogenous MMP-9) or with incubation with MMP-9, and values (% positive cells) for control siRNA-transfected cells in each case were normalized to 1. α4 silencing significantly decreased the constitutive levels of membrane-bound MMP-9 to 0.43 (α4 1 ) and 0.33 (α4 2 ), compared to their corresponding control (Fig. 6e) . Upon incubation with MMP-9, these levels were also significantly lower (0.76 and 0.64, respectively, for α4 1 and α4 2 siRNAs) than in control cells (Fig. 6e) .
We next determined whether α4 silencing and reduced membrane-bound MMP-9 affected CD99 expression. qPCR analyses demonstrated that CD99 mRNA was higher on α4 silenced-cells, both without (1.35-fold and 1.55-fold, respectively, for α4 1 and α4 2 ) or with incubation with MMP-9 (1.42-fold for α4 1 and 1.43-fold for α4 2 ), compared to their corresponding control (Fig. 6f) . Cell surface expression of CD99 was also significantly higher in α4-silenced-cells, in the absence (1.37-fold and 1.46-fold for α4 1 and α4 2 , respectively) or presence (1.35-fold and 1.20-fold, respectively) of exogenous MMP-9 (Fig. 6g) . These results indicated that MMP-9 regulated CD99 expression via binding to α4β1 integrin at the CLL cell membrane.
MMP-9 downregulates CD99 via Sp1 inactivation
The preceding results indicated that MMP-9 regulated CD99 at the transcriptional level. Because in previous reports it was shown that Sp1 is the major inducer of CD99 expression in cancer cell lines [29, 30] , we studied whether Sp1 regulated CD99 in CLL cells. In initial experiments, we incubated primary CLL cells with the Sp1 inhibitor mithramycin and measured CD99 expression after 24 h. An NF-κB inhibitor was also included as control in these experiments. Mithramycin significantly and nearly completely reduced CD99 mRNA expression in a Mock-cells and MMP-9 cells were labeled with BCECF-AM and added to 96-well plates coated with 2.5 μg/ml VCAM-1 or FN-H89. After 60 min, cell adhesion was measured using a fluorescence analyzer. g The adhesion of 10 5 primary CLL cells (four patients), transfected with the indicated siRNAs, to FN-H89 or VCAM-1 was analyzed as explained in (f). Protein load for Western blotting: 25 μg; Ctrol control, MFI mean fluorescence intensity. *P < 0.05; **P < 0.01; ***P < 0.001 concentration-dependent manner (Fig. 7a ). Reduction at the protein level was moderate but also significant, perhaps reflecting a higher stability of CD99 at the cell surface (Fig.  7b) . The NF-κB inhibitor did not affect CD99 expression (Fig. 7a, b) .
We next determined whether MMP-9 regulated CD99 via Sp1. Incubation of primary CLL cells with MMP-9 significantly diminished Sp1 phosphorylation, measured after 2 and 24 h, but had no effect on phospho-p65 levels (Fig. 7c) . To complement these results, we transfected CLL cells with MMP-9 1 siRNA or a control siRNA and measured the levels of phopho-Sp1 and phospho-p65 after 24 h of transfection. Gene-silencing MMP-9 significantly increased phospho-Sp1, without affecting phospho-p65 (Fig. 7d) . Gene-silencing α4 integrin also significantly increased phospho-Sp1, measured 48 h after transfection with the specific siRNA, while the levels of phospho-p65 did not change (Fig. 7e) . Altogether, these results demonstrated that binding of MMP-9 to α4β1 integrin induced Sp1 dephosphorylation, leading to CD99 downregulation.
CLL cells present in bone marrow have lower CD99 surface expression and Sp1 phosphorylation than their peripheral blood counterparts present in bone marrow (BM) express more cell-bound MMP-9 than their peripheral blood (PB) counterparts [8] , we reasoned that CD99 expression would be reduced in BM-derived cells. To address this, CLL cells from BM and PB of the same individuals were analyzed by flow cytometry. We first confirmed in the six patients studied that BM cells displayed higher expression of surface MMP-9 than their PB counterparts (Fig. 8a) . In correlation with this, CD99 expression was significantly lower (average 24.5%) in BM cells than in PB cells (Fig. 8b) . In accordance with the reduced CD99 expression, BM cells had significantly lower levels of phospho-Sp1 than PB cells, while the levels of phospho-p65 were similar in both cell types (Fig. 8c) . These results clearly established that the outline mechanism of CD99 downregulation by elevated levels of MMP-9 is active in CLL.
Discussion
To better understand the contribution of MMP-9 to CLL progression, particularly its role in cell migration/arrest, we have studied whether MMP-9 modulated gene expression. Our major findings are: (1) MMP-9 affects the transcriptional profile of CLL cells; (2) CD99 is an MMP-9 target and a novel contributor to CLL cell migration and adhesion; (3) CD99 downregulation requires MMP-9 binding to α4β1 integrin and Sp1 inactivation; and (4) this regulatory mechanism is active in the CLL BM.
Gene-expression analyses indicated that MMP-9 affects the expression of many genes in CLL cells. These genes were mainly allocated to immune response, intracellular signaling, and cell adhesion/migration functions. This is in agreement with the known role of MMP-9 siRNA:Ctrol MMP-9 1 Ctrol α4 1 siRNA: Fig. 7 MMP-9 downregulates CD99 via Sp1 inactivation. Totally, 5 × 10 6 CLL cells were treated with the Sp1 inhibitor mithramycin (Mit) or an NF-κB inhibitor at the indicated doses. After 24 h CD99 mRNA (a) and cell surface expression (b) was determined. c Primary CLL cells (four patients) were incubated or not with MMP-9 for the indicated times and the phosphorylation of Sp1 (at T453) and p65 (at S536) was measured by Western blotting. d, e CLL cells were transfected with MMP-9 1 (d) or α4 1 (e) siRNAs and the phosphorylation of Sp1 and p65 was measured by Western blotting. Totally, 25 μg protein/condition were loaded for Western blotting analyses. Values compared for statistical significance are those of CLL cells under the various conditions versus their respective control. FC fold change, MFI mean fluorescence intensity, Ctrol control; *P < 0.05; **P < 0.01; ***P < 0.001 in CLL cell migration [5-7, 10, 12] , and with its strong association with immune functions [31, 32] . The gene regulatory effect of MMP-9 was partly observed in MMP9Mut-cells and in primary CLL cells incubated with MMP-9MutE, indicating that this function involved only in part the MMP-9 catalytic activity. Accordingly, CD99, CD226, CD274, CXCR3, or CD52 were not identified as direct MMP-9 substrates in a degradome analysis by quantitative proteomics [33] . In general, however, MMP-9 was more efficient than MMP-9MutE, both at the gene and protein level regulation. This is consistent with the reported partial effect of MMP-9MutE in the in vitro and in vivo migration of CLL cells and MMP-9MutE-cells [10, 14] , and suggests the contribution of several MMP-9 regions, one of them being the catalytic domain, to fully achieve these functions.
A crucial finding in our study is that the results obtained in the model system of MEC-1 cell transfectants were reproduced by incubating primary CLL cells with MMP-9 and, for some genes/proteins, with MMP-9MutE. The MMP-9 gene regulatory effect was clearly significant in CLL cells but more limited than in MEC-1 cells. These quantitative differences might be explained in the context of the two cell systems used. Stable transfection of MMP-9 in MEC-1 cells may provide a sustained stimulus and in a homogenous cell population, while in primary CLL cells the response to MMP-9 is likely heterogeneous and more moderate. The selected genes/proteins regulated in primary CLL cells were CD226, CD274 CD52, and CD99, the first three with known functions in CLL [19, 20, 34] . To date, no role has been attributed to CD99 in CLL and we have chosen this molecule for further studies concerning its regulation by MMP-9.
CD99 is a transmembrane protein with two isoforms, I and II, which arise by alternative splicing of the CD99 gene [26, 27] . The expression of these isoforms is cell-type specific and CD99-I is the predominant form in hematopoietic cells [26, 35, 36] . In agreement with this, CLL cells mainly expressed CD99-I, while CD99-II was barely detected. In some cell systems, CD99 isoforms have opposite functions in cell migration and adhesion, two closely related pocesses [26] . For example, CD99-I and CD99-II inhibited or induced, respectively, osteosarcoma cell migration by inversely modulating c-Src activity [37] and inhibiting ROCK2 [38] . However, CD99-I also supports cell migration, having a well-characterized role in leukocyte transendothelial migration, where it functions sequentially after PECAM1 and forms a signaling complex with soluble adenyl cyclase, PKA and ezrin [24] [25] [26] . Indeed, CD99-I induced migration in monocytes [39] , CD34+ cells [40] , and malignant glioma cells [41] , indicating a dual role for CD99-I, likely depending on the cell context. Our present results are the first to demonstrate a supportive role for CD99-I in CLL cell migration. CD99 was also shown to modulate α4β1 integrin binding to VCAM-1 and increased T cell adhesion to endothelium [28] . Likewise, CD99 upregulated the LFA-1/ICAM-1 interaction, inducing B and T cell homotypic adhesion [27, 36] or neutrophil arrest in venules [42] . The adhesion of glioma cells to laminin was also regulated by CD99 [41] . We now show that gene-silencing CD99 diminished CLL cell adhesion to the α4β1 integrin ligands VCAM-1 and FN-H89, establishing a novel role for CD99 in the regulation of integrin function in CLL. Other reported properties for CD99 include its role CD99 in apoptosis and lymphocyte development [26, 35] . CD99 was proposed to be a marker for minimal residual disease in acute lymphoblastic leukemia [43] . In solid tumors, CD99 may be expressed at high (Ewing sarcoma and B-cell lymphoma) or low levels (Hodgkin's lymphoma and gastric carcinoma), the latter suggesting an oncosuppressor function [35] . Modulation of CD99 expression, as we observe in our study, may therefore have important consequences for malignant cells. Future studies should determine whether CD99 is involved in other pathological processes in CLL
We have addressed the mechanism by which MMP-9 regulates CD99. Our results show that this regulation required MMP-9 binding to α4β1 integrin at the cell surface. We previously reported that the MMP-9-α4β1 integrin interaction induces survival signaling [8] and impairs in vitro and in vivo CLL cell migration, by affecting migration regulatory pathways [7, 8] . Both of these functions involved MMP-9 catalytic and noncatalytic activities. We now expand these studies and report a novel signaling MMP-9 function, also elicited upon binding to CLL cells via α4β1 integrin, consisting in the regulation of CD99 expression. CD99 is therefore part of the mechanism by which MMP-9 impairs CLL cell migration.
Our results further demonstrate that downregulation of CD99 involves inactivation of the Sp1 transcription factor. Sp1 was shown to positively regulate CD99 in lymphoma, embryonic kidney cells, and gastric carcinoma [29, 30] . The transcriptional activity of Sp1 is tightly regulated, being influenced by its phosphorylation state, other posttranslational modifications, and/or interaction with other nuclear factors, which may induce or repress Sp1-mediated transcription [44, 45] . In our study, the following evidences support the involvement of Sp1 in CD99 downregulation by MMP-9: (1) The Sp1 inhibitor mithramycin reduced CD99 expression in a dose-dependent manner; (2) Sp1 phosphorylation was constitutively lower in MEC-1 MMP-9-cells than in Mock-cells and was significantly decreased in primary CLL cells upon incubation with MMP-9; and (3) gene-silencing α4 integrin or MMP-9 significantly increased Sp1 phosphorylation and CD99 cell surface expression. Sp1 inactivation is therefore a novel consequence of MMP-9 binding to α4β1 integrin in CLL cells. The fact that Sp1 also regulates genes involved in proliferation/survival, angiogenesis and stress response [45] highlights the relevance of the MMP-9-α4β1 integrin interaction in CLL cells.
It is now demonstrated that elevated α4 integrin expression (>30%) constitutes an unfavorable prognostic marker in CLL [46] . α4β1 integrin induces cell survival, drug resistance and is required for CLL cell homing to BM, all contributing to disease progression [3, 6, 8, 47] . Our present results demonstrate that the MMP-9-α4β1-induced CD99 regulation is active in the pathophysiological context of CLL. This was not inferred from examination of MMP-9 and CD99 expression in PB CLL cells, since no correlation was observed in all cases. Therefore, the constitutive MMP-9 synthesized or bound by circulating CLL cells may not be sufficient to impact on gene/protein expression. We previously showed [8] and confirmed here that CLL cells isolated from lymphoid organs have higher membranebound MMP-9 than their PB counterparts, reflecting the higher MMP-9 levels present in these niches. Consistent with the increased MMP-9 expression, BM-derived CLL cells expressed lower CD99 and phospho-Sp1 levels than PB-derived cells from the same individual. These findings unequivocally demonstrate that downregulation of CD99 by elevated levels of MMP-9 is actively induced in BM as a CLL niche.
Our results are in accordance with previous gene expression analyses (dataset GSE21029) showing lower CD99 expression in BM-derived CLL cells than in PB-CLL cells [48] . This was not the case for CD99 expression in lymph node-derived CLL cells, indicating mechanistic differences likely due to the distinct molecular signatures observed among CLL tissues [49] . MMP-9 regulation of CD99 may thus be an important molecular process for CLL cells in the BM. Because we previously showed that high MMP-9 expression impairs CLL cell migration [7, 10] , downregulation of CD99 may represent a critical mechanism controlling CLL cell traffic and arrest. CLL cells entering BM would be exposed to high concentrations of MMP-9 which, upon binding to α4β1 integrin, would downregulate CD99 and favor retention in this organ. Because cells in the BM receive survival and proliferative signals, regulation of CD99 by MMP-9 may directly impact CLL progression. This cell arrest effect is in sharp contrast with an old dogma stating that MMPs are purely stimulators of cancer cell invasion and metastasis.
In summary, our study is the first to demonstrate that MMP-9 regulates gene and protein expression in CLL. It also identifies CD99 as an MMP-9 target and a novel contributor to CLL cell migration and retention in the BM. MMP-9 and CD99 may therefore represent therapeutic targets in CLL.
Materials and methods
Patients, cells, and cell cultures
Approval was obtained from the CSIC Bioethics Review Board for these studies. PB samples from the 39 untreated CLL patients listed in Supplementary Table S3 
Cell adhesion assays
These assays were performed on 96-well plates coated with 0.5% bovine serum albumin (BSA) or 2.5 µg/ml VCAM-1 or FN-H89 [6] . Totally, 10 5 MEC-1 or primary CLL cells were incubated with 1.4 ng/ml 2,7-bis(carboxyethyl)-5(6)-carboxyfluoresceinacetoxymethyl ester (BCECF-AM, Molecular Probes, Eugene, OR) for 30 min, suspended in RPMI 1640, 0.5% BSA, and added to the coated wells. After 45 min at 37°C, attached cells were lysed with PBS, 0.1% SDS and quantified using a fluorescence analyzer (BMG Labtech, Offenburg, Germany).
Cell migration assays
For chemotaxis assays, 3 × 10 5 cells in medium were added to the upper chamber of Transwell filters (Costar, New York, NY) and allowed to migrate towards medium containing 200 ng/ml CCL21 in the lower chamber. After 24 h at 37°C, migrated cells were counted by flow cytometry. For transendothelial migration, 7.5 × 10 4 HUVEC were plated on fibronectin-coated (10 μg/ml) Transwell filters and confluent monolayers were stimulated with 15 ng/ml TNF-α for 16 h before the assay. CLL cells (3 × 10 5 ) were added to the HUVEC monolayer and transmigration towards medium containing CCL21 was monitored after 24 h as above.
Cells that migrated in both types of assays were expressed as percentage of the total number of cells added, also counted by flow cytometry.
